

Title (en)
COMPOSITIONS AND METHODS FOR TREATING CANCER

Title (de)
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON KREBS

Title (fr)
COMPOSITIONS ET MÉTHODES POUR TRAITER LE CANCER

Publication
EP 4185326 A1 20230531 (EN)

Application
EP 21846587 A 20210723

Priority
• US 202063056266 P 20200724
• US 202063123751 P 20201210
• US 2021042973 W 20210723

Abstract (en)
[origin: WO2022020720A1] Disclosed herein are methods for treatment of a mesothelin (MSLN)-expressing cancer in a human subject comprising administration of, e.g., a plurality of anti-MSLN T cell receptor fusion protein (TFP)- expressing T cells. The human subject described herein may have been previously administered with one or more lines of prior therapy before the administration of the plurality of anti-MSLN TFP-expressing T cells.

IPC 8 full level
A61K 39/395 (2006.01); **C07K 14/725** (2006.01)

CPC (source: EP)
A61K 39/4611 (2023.05); **A61K 39/464468** (2023.05); **A61K 45/06** (2013.01); **A61P 35/00** (2018.01); **C07K 14/705** (2013.01); **C07K 14/7051** (2013.01); **C07K 16/30** (2013.01); **A61K 2239/31** (2023.05); **A61K 2239/38** (2023.05); **A61K 2239/55** (2023.05); **A61K 2239/59** (2023.05); **C07K 2317/569** (2013.01); **C07K 2317/622** (2013.01); **C07K 2317/73** (2013.01); **C07K 2319/03** (2013.01); **C07K 2319/33** (2013.01); **C12N 5/0636** (2013.01); **C12N 2510/00** (2013.01)

C-Set (source: EP)
A61K 39/464468 + A61K 2300/00

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

Designated validation state (EPC)
KH MA MD TN

DOCDB simple family (publication)
WO 2022020720 A1 20220127; **WO 2022020720 A9 20220217**; EP 4185326 A1 20230531

DOCDB simple family (application)
US 2021042973 W 20210723; EP 21846587 A 20210723